ASIA BEAT: Walking the communication tightrope
This article was originally published in Scrip
Big Pharma is working hard to make its voice heard across Asia this week. Or at least the European research-based industry is, which shares many of the same strategic concerns as its US and Japanese counterparts.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.